- Home
- FUTU vs EXAS Comparison
FUTU vs EXAS Comparison
Compare FUTU & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUTU
- EXAS
- Stock Information
- Founded
- FUTU 2011
- EXAS 1995
- Country
- FUTU Hong Kong
- EXAS United States
- Employees
- FUTU N/A
- EXAS N/A
- Industry
- FUTU Investment Bankers/Brokers/Service
- EXAS Medical Specialities
- Sector
- FUTU Finance
- EXAS Health Care
- Exchange
- FUTU Nasdaq
- EXAS Nasdaq
- Market Cap
- FUTU 15.1B
- EXAS 8.8B
- IPO Year
- FUTU 2019
- EXAS N/A
- Fundamental
- Price
- FUTU $107.52
- EXAS $43.04
- Analyst Decision
- FUTU Buy
- EXAS Strong Buy
- Analyst Count
- FUTU 4
- EXAS 18
- Target Price
- FUTU $85.50
- EXAS $70.59
- AVG Volume (30 Days)
- FUTU 3.2M
- EXAS 2.6M
- Earning Date
- FUTU 03-13-2025
- EXAS 05-07-2025
- Dividend Yield
- FUTU 1.81%
- EXAS N/A
- EPS Growth
- FUTU 27.23
- EXAS N/A
- EPS
- FUTU 5.01
- EXAS N/A
- Revenue
- FUTU $1,541,380,749.00
- EXAS $2,758,867,000.00
- Revenue This Year
- FUTU $38.77
- EXAS $13.02
- Revenue Next Year
- FUTU $18.69
- EXAS $13.02
- P/E Ratio
- FUTU $22.32
- EXAS N/A
- Revenue Growth
- FUTU 31.60
- EXAS 10.37
- 52 Week Low
- FUTU $51.80
- EXAS $40.62
- 52 Week High
- FUTU $130.88
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- FUTU 49.16
- EXAS 29.29
- Support Level
- FUTU $104.15
- EXAS $44.45
- Resistance Level
- FUTU $122.64
- EXAS $46.99
- Average True Range (ATR)
- FUTU 7.31
- EXAS 2.45
- MACD
- FUTU -1.40
- EXAS -0.22
- Stochastic Oscillator
- FUTU 28.34
- EXAS 9.95
About FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.